Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on December 9, 2010, regarding an event that occurred on December 8, 2010. The filing addresses corporate governance changes specifically related to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters rather than financial performance.
Material Changes
The primary material change reported is the election of Marsha H. Fanucci as a Class II director by the Board of Directors. Her term is set to expire at the annual meeting of stockholders in 2012.
Guidance, Outlook, and Compensation
In connection with her election, Ms. Fanucci received a stock option grant for 30,000 shares of the Company's common stock. These options vest annually over a three-year period. Additionally, she will be compensated as a director in accordance with the Company's policy for non-employee directors, as detailed in the Proxy Statement for the 2010 Annual Meeting of Stockholders.
Key Facts for Investor Verification
- Marsha H. Fanucci was elected as a Class II director on December 8, 2010.
- Ms. Fanucci received a grant of 30,000 stock options vesting over three years.
- Her director term expires at the 2012 annual meeting of stockholders.
- Director compensation follows the policy outlined in the April 20, 2010 Proxy Statement.